Abbott Laboratories (NYSE:ABT) Price Target Cut to $132.00 by Analysts at Oppenheimer

Abbott Laboratories (NYSE:ABT) had its price target decreased by analysts at Oppenheimer from $140.00 to $132.00 in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage presently has an “outperform” rating on the healthcare product maker’s stock. Oppenheimer’s target price would indicate a potential upside of 21.45% from the company’s previous close.

A number of other equities research analysts have also recently commented on the stock. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Mizuho increased their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 14th. Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Daiwa Capital Markets lifted their target price on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $147.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $143.37.

Abbott Laboratories Stock Performance

ABT traded up $0.08 during trading on Friday, hitting $108.69. The company’s stock had a trading volume of 2,307,181 shares, compared to its average volume of 8,972,974. Abbott Laboratories has a one year low of $105.78 and a one year high of $141.23. The business’s 50 day simple moving average is $125.23 and its 200-day simple moving average is $128.54. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The firm has a market cap of $189.00 billion, a PE ratio of 13.65, a P/E/G ratio of 2.00 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Hedge funds have recently made changes to their positions in the business. IMG Wealth Management Inc. raised its position in Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter worth $31,000. Finally, Anfield Capital Management LLC raised its stake in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell‑side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double‑digit devices, mid‑single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi‑year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long‑term investors because Abbott remains a cash‑generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near‑term expectations but keeps mid/longer‑term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near‑9% year‑over‑year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell‑off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine‑based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.